InflaRx N.V.


Download Data

InflaRx N.V. Market Capitalization on June 03, 2024: USD 93.04 M

InflaRx N.V. Market Capitalization is USD 93.04 M on June 03, 2024, a -60.66% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.
  • InflaRx N.V. 52-week high Market Capitalization is USD 264.98 M on June 16, 2023, which is 184.82% above the current Market Capitalization.
  • InflaRx N.V. 52-week low Market Capitalization is USD 69.96 M on May 10, 2024, which is -24.80% below the current Market Capitalization.
  • InflaRx N.V. average Market Capitalization for the last 52 weeks is USD 139.30 M.

InflaRx N.V.

CEO Dr. Niels C. Riedemann M.D., Ph.D.
IPO Date Nov. 8, 2017
Location Germany
Headquarters Winzerlaer Str. 2, Jena, Germany, 07745
Employees 62
Sector Healthcare
Industry Biotechnology

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Similar companies


Generation Bio Co

USD 3.06



Edgewise Therapeutics Inc

USD 17.41



Acumen Pharmaceuticals Inc

USD 2.75



Eledon Pharmaceuticals Inc

USD 2.80



Icosavax Inc




Monte Rosa Therapeutics Inc

USD 3.98



Design Therapeutics Inc

USD 4.07



Werewolf Therapeutics Inc

USD 3.99



Stoke Therapeutics Inc

USD 15.48


StockViz Staff

July 25, 2024

Any question? Send us an email